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Background: Biochemical parameters, such as C-reactive protein (C-RP), Procalcitonin (PCT), Lactate dehydro
genase (LDH) and Ferritin are associated with COVID-19 severity and prognosis. This trend analysis of COVID-19
prognostic biomarker requisitions is aimed at providing a reflection of the clinical practices adopted amidst the
peak of the pandemic. This knowledge of the prognostic biomarkers utilized, will further aid to classify patients
based on their risk, for optimal resource allocation and improve outcomes.
Material & methods: This cross-sectional study was conducted at the clinical chemistry laboratory at the Aga Khan
University Hospital (AKUH), Karachi Pakistan. A team consisting of two clinical chemistry consultants reviewed
the COVID-19 prognostic biomarkers tests performance data from March to July 2020 using the integrated
laboratory information management system (ILMS). The test statistics of March to July 2020 when COVID-19
cases were on the rise in the country were compared with those of the same months from 2019. The changes
in the test groups were expressed in percentages. Microsoft Excel for windows 2019 was used for data analysis.
Results: The total specimens received for testing in 2020 (n = 574,092) showed a percent decline of approxi
mately (− ) 33% compared to 2019 (n = 858,756). Contrary to the overall decline in volumes an upward surge
was noted for the prognostic biomarkers. From March to July, the highest percent change was noted for LDH
(+155.1%), followed by PCT (+66.7.1%), C-RP (+26.5%) and Ferritin (+22.1%) in 2020 compared to the same
time frame in 2019. The highest percent change was noted in June.
Conclusion: During the COVID 19 pandemic, a significant increase in utilization of laboratory services was seen
for COVID-19 prognostic markers.

1. Introduction
The Coronavirus Disease 2019 (COVID-19) pandemic, a respiratory
and systemic viral disease, caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), emerged on the global health scenario in
late December 2019 and becoming a global pandemic in 2020 [1].
Clinical laboaratories have played a critical role in managing the
pandemic [2]. Even though the clinical laboratories continued their
operations 24/7, the lockdown and restrictions imposed by most coun
tries to decrease the risk of contagion, have affected the course of routine
medical services [3].
In this era of unprecedented health crisis, in addition to rapid and
accurate diagnostic tests, the clinical laboratory specialists were in
search for reliable biomarkers associated with COVID-19 disease pro
gression, in order to stratify high risk subjects, particularly in resource
constrained setups for optimal intensive care [4].

COVID-19 patients are classified into mild, moderate, severe, and
critical disease [5]. Various studies have reported biochemical param
eters, such as C-reactive protein (C-RP), Procalcitonin (PCT), Lactate
dehydrogenase (LDH) and Ferritin to be associated with COVID-19
severity and prognosis [3]. The increase in inflammation markers and
acute phase reactants are linked with the underlying systemic vasculitic
processes and the cytokine storm that cause most parenchymal lesions in
vital organs [3].
On one end, amid the COVID-19 pandemic, the delay of non-urgent
health services and subsequent decline in the number of patients due to
concern of contagion, is expected to lead to a significant drop in the
overall routine biochemical test requisitions, while on the other, a rapid
surge in the test requests for the COVID-19 prognostic biomarkers is
projected. At our institute, a tertiary care hospital in the metropolis of
Karachi, during the lockdown and restrictions, all elective, semi-elective
procedures and non-essential procedures were cancelled. From April to
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June 2020, our pediatric surgery department, performed only one-third
the volume compared to the preceding three months [6]. Moreover, the
number of clinics in each specialty was cut down and tele-clinics were
also introduced from beginning of April [7].
The aim of this study was to investigate the trend in COVID-19
prognostic biomarkers requisitions including C-RP, PCT, LDH and
Ferritin, at a high-volume clinical chemistry laboratory in Pakistan
during the peak pandemic months. Furthermore, the test statistics of
March to July 2020 when COVID-19 cases were on the rise were
compared with those of 2019. While much was unknown about the
course of COVID-19 disease, the clinicians utilized some of the lessons
learnt from previous experiences and knowledge for prognostic
biomarker selection. This trend analysis of COVID-19 prognostic
biomarker requisitions is aimed at providing a reflection of the clinical
practices adopted amidst the peak of the pandemic. This knowledge of
the prognostic biomarkers utilized, will further aid to classify patients
based on their risk, for optimal resource allocation and improve
outcomes.

574,092) showed a percent decline of approximately (− ) 33% compared
to 2019 (n = 858,756). Contrary to the overall decline in volumes an
upward surge was noted for the prognostic biomarkers i.e. the total
specimen volume received for testing in 2020 (n = 71,548) showed
41.4% increase compared to 2019 (n = 50,601). In totality, from March
to July, the highest percent change was noted for LDH (+155.1%), fol
lowed by PCT (+66.7.1%), C-RP (+26.5%) and Ferritin (+22.1%) in
2020 compared to the same time frame in 2019. The highest percent
change was noted in June for all the biomarkers, the highest being LDH
(+483.1) followed by Ferritin, PCT and C-RP respectively.
On further stratification into monthly volumes, the percent change
noted for these biomarkers in 2020 compared to 2019 is elaborated in
Table 2. Fig. 1 presents a graphical depiction of trend analysis of the four
prognostic biomarkers test volumes recorded in 2020 compared to the
subsequent months in 2019.
4. Discussion
The test requisition data shows a general surge in the four prognostic
biomarkers utilization amid the COVID-19 pandemic. This study depicts
that PCT demonstrated a positive trend right from March 2020
compared to the other three biomarkers, which were initially lower
compared to 2019 in March and April. PCT is an established biomarker
to differentiate bacterial from viral infections, and a meta-analysis re
ported a ~5-fold higher risk of severe COVID-19 infection associated
with elevated PCT [9,10]. However, a paradigm shift was observed in
May 2020 when a steady increase in test requests was noted for all the
four biomarkers.
This variation in trend could be linked to several reasons, for instance
May 2020 was regarded as the month when the cases of COVID-19
exhibited a rapid upheave in Pakistan [11]. Additionally, the strict
lockdown imposed in late March restricted patient movements leading
to a decline in test volumes, which gradually improved as the re
strictions were subsequently relaxed in the following months beginning
around May 10, 2020 [12]. Additionally, the hospital to which the

2. Methods
This retrospective observational study was conducted at the clinical
chemistry laboratory at the Aga Khan University Hospital (AKUH),
Karachi Pakistan, which serves as a national reference lab for the
country. With its growing network of more than 260 phlebotomy centers
and outreach laboratories spread across Pakistan, it caters to test re
quests from all the provinces. The laboratory operates to highest stan
dards of quality and was the first lab to be accredited by College of
American Pathologists (CAP) as well as Joint Commission International
Accreditation (JCIA).
A team consisting of two clinical chemistry consultants reviewed the
COVID-19 prognostic biomarkers tests performance data from March to
July 2020 using the integrated laboratory information management
system (ILMS). The test statistics of March to July 2020 when COVID-19
cases were on the rise in the country were compared with those of the
same months from 2019.
Frequencies and percentages were analyzed for confirmed cases of
covid-19, active cases of covid-19, deaths, recoveries, total specimen
count and total prognostic biomarkers specimen count of 2019 and 2020
respectively. The test requisition statistics of prognostic biomarkers
volumes for March to July in 2019 and 2020 were compared; and the
changes in the test groups were expressed in terms of percent change
alongside its graphical representation. Microsoft Excel for windows
2019 was used for data analysis.

Table 2
Percent change in COVID-19 prognostic biomarkers volumes for March to July
in 2019 and 2020.
March 2019 (n)
March 2020 (n)
Change (%)
April 2019 (n)
April 2020 (n)
Change (%)
May 2019 (n)
May 2020 (n)
Change (%)
June 2019 (n)
June 2020 (n)
Change (%)
July 2019 (n)
July 2020 (n)
Change (%)

3. Results
A descriptive detail of the total confirmed cases, active cases, deaths
and recoveries according to the data collected by the Government of
Pakistan alongside the change in total specimens received and the four
prognostic biomarkers specimens received based on a comparison be
tween 2019 and 2020 for the months from March to July is shown in
Table 1 [8].
Furthermore, the total specimens received for testing in 2020 (n =

C-RP

LDH

PCT

Ferritin

5935
4069
− 31.4
5680
3648
− 35.8
4944
5238
+5.9
4439
11,395
+156.7
5110
8664
+69.5

974
687
− 29.5
948
1115
+17.6
894
1743
+94.9
872
5085
+483.1
967
3247
+235.8

1199
1292
+7.8
1011
1226
+21.3
1026
1603
+56.2
1041
2686
+158.0
1188
2305
+94.0

2920
1552
− 46.8
3174
1690
− 46.8
2758
2782
+0.8
2435
6436
+164.3
3086
5085
+64.8

Table 1
COVID-19 cases in Pakistan and the trend of change in total number of specimens and prognostic biomarkers specimens’ data of March to July 2020 compared to same
time period in 2019.
Months

Confirmed Cases of
COVID-19 (n)

Active Cases of
COVID-19 (n)

Deaths
(n)

Recoveries
(n)

Total Specimen
count 2019 (n)

Total Specimen
count 2020 (n)

Total Prognostic
Biomarkers Specimen
2019 (n)

Total Prognostic
Biomarkers Specimen
2020 (n)

March
April
May
June
July

2039
16,817
72,460
213,470
279,146

1931
12,117
44,834
108,273
25,149

26
385
1543
4395
5970

82
4315
26,083
100,802
248,027

188,710
192,966
153,898
146,784
176,398

125,321
81,574
95,857
132,017
136,323

11,028
10,813
9622
8787
10,351

7600
7679
11,366
25,602
19,301
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Fig. 1. A comparison of COVID-19 prognostic biomarkers volumes for March to July in 2019 and 2020.

laboratory is affiliated with, started a dedicated COVID-19 inpatient
facility which further enhanced test requisition flow. This establishment
alongside the tele-clinics improved routine patient inflow and the surge
in test requests was evident.
The highest number of active cases in Pakistan were recorded in
June, which is in agreement with our data as an average of +240.5%
hike in prognostic biomarkers test utilization was noted, which was
significantly higher than the previous three months of 2020. Compared
to the other three prognostic markers, significantly higher utility of LDH
was noted. LDH is a cytoplasmic glycolytic enzyme found in almost
every tissue, and its elevation generally indicates tissue damage. The
role of elevated LDH has been previously well established in patients
infected with MERS-CoV, H7N9, and H5N1 [13]. It has been widely
accepted as an independent predictor of mortality for patients with se
vere acute respiratory syndrome and H1N1 infection [14]. Its previous
strong association with prognosis in acute respiratory distress syn
dromes could be one reason for the increased requisition by physicians.
On further evaluation, the number of requisitions declined signifi
cantly during July compared to June 2020. This trend is in line with the
COVID-19 country statistics, as Pakistan demonstrated a flattening of
the disease curve in July 2020 [15].
The total specimen count in 2020 was lower during the peak
pandemic months, a major contributor being lock down and movement
restrictions. Even though, the hospital conceived a recovery plan for
medical and surgical services and switched from ‘crisis mode’ to ‘back to
usual’ the overall volumes remained low compared to the time span of
2019 for the duration of this study. The potential reasons being the
apprehensions of the patients and their families alongside the fear of

contracting the virus from visiting medical and diagnostic facilities,
while waiting in patient areas or being exposed while being treated, that
have not been adequately alleviated despite the plateau in the number of
cases. Subsequently, a significant drop in the overall routine biochem
ical test requisitions, while on the other, a rapid surge in the test requests
for the COVID-19 prognostic biomarkers was evident as shown by this
study.
Several guidelines were issued in response to pandemic preparedness
that primarily focused on containment, treatment and diagnostic mo
dalities. Meanwhile, there was also a dire need for early risk stratifica
tion systems and biomarkers to predict disease progression and to
identify high-risk patients at an early stage of the infection. During the
COVID 19 pandemic while there was a significant reduction in overall
laboratory requisitions owing to reduction in out-patient clinics and
elective procedures, a significant increase in utilization of laboratory
services was seen for C-RP, PCT, LDH and Ferritin. This elevated trend of
prognostic biomarkers requisitions showed that while much was un
known about the course of COVID-19 disease, the clinicians utilized
some of the lessons learnt from previous experiences and knowledge of
MERS-CoV, H7N9, and H5N1 and as more details regarding COVID
clinical course, pathologies and possible useful interventions emerged in
literature, clinicians utilized the laboratory services to good effect. This
approach can optimize management goals, and overcome the shortage
of medical and material resources which was particularly evident amidst
this global emergency. As identification of reliable outcome predictors
in COVID-19 is of paramount importance for improving patient’s man
agement, while this specific objective was beyond the scope of this
study, various studies have shown improved outcome, based on the
524
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prognostic utility of abnormal inflammatory and organ injury circu
lating biomarkers [16,17].
There were certain limitations of this study, as the evaluation of
patients’ information/database was not performed, this study cannot
demarcate between tests requisitions specifically pertaining to COVID19 proven cases and those requested in routine clinical care of other
disorders.

the data, and controlled the decision to publish.
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5. Conclusion
As the data on the use of selective biomarkers becomes available
which showed more affective patient management and improved out
comes, it has now become a standard practice to test for these prognostic
biomarkers once a patient tests positive for COVID-19. Clinical labora
tories should be prepared for the optimal inventory management in the
pandemic era owing to the varying trend of biomarkers utilizations, as
well as potential interruption of international trade. Moreover, delayed
health care requirements are further expected to increase the work flow
to the hospitals acutely as the restrictions are lifted. Therefore, the na
tional case statistics should be carefully followed and resources of both
personnel and materials should be pre-planned by the laboratory
stakeholders.
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